Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Bivalent IRE1a regulation of epithelial cell fate and function in muco-obstructive lung disease

Award Number: F32HL186611
ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: FELLOWSHIP/SCHOLARSHIP/STUDENT LOANS
PERIOD OF PERFORMANCE START DATE: 12/01/2026
PERIOD OF PERFORMANCE END DATE: 11/30/2027

Group Awards By:

View Award Description

Bivalent IRE1a regulation of epithelial cell fate and function in muco-obstructive lung disease - Project Summary/Abstract The work proposed in this fellowship application focuses on the training of Dr. Nathaniel Harder in studying the mechanisms of IRE1α-mediated obstructive lung disease pathogenesis. The goals include leveraging advanced models of human biology and disease, and computational biology and bioinformatics to elucidate ER stress pathway mechanisms by which lung epithelial cell fate and function are altered. With the support and guidance of Drs. David Erle and Vincent Auyeung at UCSF, the proposed research aims will investigate the bivalent mechanisms of action of IRE1α, regulation of both XBP1’s transcriptional activity and Regulated IRE1α-Dependent Decay (RIDD), through two distinct aims. Aim 1 will test the hypothesis that XBP1 acts both on and synergistically with the goblet cell master transcription factor FOXA3. When activated by IRE1α, XBP1 can alter basal fate and lead to goblet cell metaplasia, a key pathology of certain obstructive lung diseases. Preliminary data analyzed by Dr. Harder has demonstrated potential regulatory coordination between XBP1 and FOXA3 which will be investigated though analysis of XBP1 binding to the enhancer region of FOXA3 (aim 1.1), the co-regulation of genes through collaborative enhancer binding of XBP1 and FOXA3 (aim 1.2), and the molecular interactions of the two transcription factors (aim 1.3). Aim 2 will test the hypothesis that RIDD controls ciliated cell differentiation and function. In cells treated with an inhibitor of IRE1α selective for RIDD, a gene related to ciliated cell fate was increased, suggesting a relationship between the RNA degradation associated with RIDD and ciliated cells. This relationship will be investigated through the analysis of lung epithelial ciliated cell function (aim 2.1), ciliated cell function (aim 2.2), IRE1α-mediated degradation of DNAH5 RNA (aim 2.3), and elucidation of pathways of ciliated cell differentiation altered by RIDD degradation (aim 2.4). Completion of these research aims is expected to lead to the identification of targetable therapeutic pathways that could restore a healthy homeostatic balance in lung epithelial cell population and function. These aims will derive additional hypotheses for future development as an independent career scientist. To ensure the training develops critical characteristics to support Dr. Harder’s career, training will include interaction with the scientific community through presentations and writing, and the development of laboratory leadership skills while upholding the rigor and ethics essential for crucial as a scientist. The Ruth L. Kirschstein National Research Service Award Individual Postdoctoral Fellowship will facilitate Dr. Harder’s evolution into an independent scientist while building his collaborative network of research professionals essential for future success.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $79,348 )
2026	2026	REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE	1855 FOLSOM ST STE 425	SAN FRANCISCO	CA	94103	SAN FRANCISCO	USA	Lung Diseases Research	000	1	5/29/2026	NEW	$79,348
														Subtotal = $79,348

Grand Total All Awards = $79,348

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Bivalent IRE1a regulation of epithelial cell fate and function in muco-obstructive lung disease

Award Number: F32HL186611

ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: FELLOWSHIP/SCHOLARSHIP/STUDENT LOANS

PERIOD OF PERFORMANCE START DATE: 12/01/2026

PERIOD OF PERFORMANCE END DATE: 11/30/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer